Back to search results

Observational Study: Monitoring Metastatic Lobular Breast Cancer with ctDNA

This observational study is looking at how circulating tumor DNA (ctDNA) changes over time in women with metastatic invasive lobular breast cancer (mILC). ctDNA is a diagnostic test called Signatera that looks for specific cancer mutations in your blood. The goal is to see if these changes in ctDNA can help doctors understand how well treatments are working early on, especially since mILC can be hard to track with regular imaging. You may be able to join if you are an adult woman with mILC that is ER+ (estrogen receptor positive) and HER2-negative. The study will measure changes in your ctDNA at baseline, 4 weeks, 8 weeks, and 12 weeks. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 20 women. It is not a treatment study, but rather aims to understand how a diagnostic test works.
What's involved
You would have blood samples taken at baseline, 4 weeks, 8 weeks, and 12 weeks to measure your ctDNA.
Compensation
Not stated in the trial record.
Follow-up
Your ctDNA will be measured over a period of 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06666439

Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer

Recruiting
Not specifiedAges 18+Observational
Julia Foldi
~20 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:circulating tumor DNA (ctDNA)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in ctDNA
Measured over Baseline, at 4 weeks, at 8 weeks, at 12 weeks

Conditions

Metastatic Invasive Lobular Carcinoma (mILC)

Explore related trials

Invasive Breast Lobular Carcinoma

NCT06666439

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Magee Women's Hospital of UPMC

    Pittsburgh, Pennsylvaniastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Julia Foldi, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Lucia Borasso, BA
[email protected]
4126413304
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Change in ctDNABaseline, at 4 weeks, at 8 weeks, at 12 weeks

    Change in circulating tumor DNA (ctDNA) is measured by MTM/ml in patients receiving first line endocrine therapy (an aromatase inhibitor or fulvestrant) for metastatic lobular breast cancer.